Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
71.4M
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
72.6M
-
Shares change
-
+13.9M
-
Total reported value, excl. options
-
$1.31B
-
Value change
-
+$264M
-
Put/Call ratio
-
0.75
-
Number of buys
-
82
-
Number of sells
-
-29
-
Price
-
$18.08
Significant Holders of Phathom Pharmaceuticals, Inc. - Common Stock (PHAT) as of Q3 2024
147 filings reported holding PHAT - Phathom Pharmaceuticals, Inc. - Common Stock as of Q3 2024.
Phathom Pharmaceuticals, Inc. - Common Stock (PHAT) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 72.6M shares
.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (10.1M shares), Medicxi Ventures Management (Jersey) Ltd (7.46M shares), JENNISON ASSOCIATES LLC (5.87M shares), Invesco Ltd. (4.1M shares), Carlyle Group Inc. (3.5M shares), BlackRock, Inc. (3.12M shares), VANGUARD GROUP INC (2.7M shares), Ensign Peak Advisors, Inc (2.58M shares), Woodline Partners LP (2.57M shares), and NEA Management Company, LLC (1.96M shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.